GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2007

Lilly In-Licenses OSI’s Diabetes Program for $25M

  • OSI Pharmaceuticals’ diabetes and obesity subsidiary, Prosidion, granted Eli Lilly and Company exclusive rights to its Glucokinase Activator (GKA) program. The program includes PSN010 currently in a Phase I trial. "This in-licensing agreement will help bolster Lilly's early-stage pipeline and will augment one of our core therapeutic areas," comments David Moller, M.D., Lilly, vp, endocrine and cardiovascular research and clinical investigation.

    Under the terms of the agreement, OSI will receive an upfront fee of $25 million, up to $360 million in potential development, sales milestones, and other payments, plus royalties on sales of any compounds successfully commercialized from the program.

    GKAs are designed to attenuate hyperglycemia by rapidly lowering blood glucose levels through a dual mechanism of increasing glucose uptake in the liver and potentiating insulin secretion from the pancreas.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?